

ORIGINAL ARTICLE

Iran J Allergy Asthma Immunol

In press.

Inhibitory Effect of Propofol on Type II Inflammation in Mice with Allergic Rhinitis

Xi Chen¹, Wenxing Liu¹, Xiaohua Guo¹, Yinhui Zeng², Xingrong Song¹, and Wenlong Liu²

¹ *Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China*

² *Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China*

Received: 7 July 2024; Received in revised form: 6 October 2024; Accepted: 23 October 2024

ABSTRACT

Propofol, a quick-acting systemic anesthetic agent widely used in general anesthesia, can alleviate airway T-helper 2 (T_H2) inflammation. Group 2 innate lymphoid cells (ILC2s) are a newly discovered group of lymphoid cells and play key roles in allergic rhinitis (AR). We aimed to investigate the regulation of ILC2s treated with propofol and its possible mechanisms in a mouse model.

An ovalbumin (OVA)-sensitized and challenged mouse model was established. Nasal lavage fluid (NLF) and tissue samples were collected for the detection of inflammatory cells, type II cytokines, and ILC2s using Giemsa staining, enzyme-linked immunosorbent assay, and flow cytometry. CD4⁺ T cells and ILC2s were cocultured and detected by flow cytometry to confirm the proportion of T_H2 cells.

Compared with OVA-sensitized and challenged mice, propofol-treated model mice presented decreased type II cytokine levels and total numbers of cells, eosinophils, neutrophils, and macrophages in NLF. Mice treated with propofol presented decreased nasal ILC2 frequency. Moreover, the nasal expression of GATA binding protein 3 (GATA3) and retinoid-related orphan receptor α (ROR α), as well as the levels of IL-5 and IL-13, were significantly inhibited after propofol treatment. Compared with those cultured alone, cocultures of ILC2s and CD4⁺ T cells resulted in significantly more T_H2 cells. When propofol was added, the percentage of T_H2 cells significantly decreased. This effect was alleviated when anti-major histocompatibility complex class II (anti-MHC II) protein was added.

Our study provides preliminary evidence that propofol can play an inhibitive role in AR by regulating innate and adaptive immunity.

Keywords: Allergic rhinitis; Group 2 innate lymphoid cells; Propofol

Corresponding Authors: Xingrong Song, MD;
Department of Anesthesiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Tel: (+98 86) 20380 76243, Fax: (+98 86) 20380 76243, Email: songxr1966@163.com

Wenlong Liu, PhD;
Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. Tel: (+98 86) 20380 76166, Fax: (+98 86) 3807 6166, Email: lwl20103@163.com

INTRODUCTION

Allergic rhinitis (AR) is a widespread health issue that is becoming more common and has significant medical and socioeconomic impacts. The investigation of biologics as potential treatments has thus far been limited to anti-immunoglobulin E (IgE) therapies and anti-inflammatory agents targeting type 2 responses.¹

Propofol, a quick-acting systemic anesthetic agent widely used in general anesthesia, is characterized by quick recovery after anesthesia, mild gastrointestinal reaction, and fewer cumulative effects after continuous administration.² Accumulating evidence suggested that propofol has certain advantages in asthma patients due to its bronchodilatory effects.^{3,4} Moreover, propofol has anti-inflammatory effects on various cells and animal models by inhibiting the production of inflammatory cytokines, such as interleukin (IL)-1b, IL-6, and tumor necrosis factor.⁵⁻⁸ Propofol alleviates airway inflammation in asthmatic mice by inhibiting T-helper 2 (T_H2) differentiation.⁹ Moreover, the inhibition of 5-hydroxytryptamine (5-HT) action by propofol is also involved in ovalbumin (OVA)-induced contraction.¹⁰ These results suggest that propofol may be a potential treatment target for AR. Although the role of propofol in T_H2 response was studied, the effects of propofol on group 2 innate lymphoid cells (ILC2s) in AR are poorly understood.

ILC2s, a new population of lymphoid cells, play important roles in the development of immune response.¹¹ ILC2 cells are particularly effective at generating IL-5, which facilitates eosinophil activation and maintenance, as well as IL-13, a cytokine that modulates various facets of airway inflammation, mucus transformation, smooth muscle adaptation, and airway hyperreactivity.¹² Previous studies have shown that the frequency of ILC2s is elevated in allergic inflammation. For example, ILC2 numbers are greater in AR patients than in controls.¹³ Our study explored the effect of propofol on ILC2s in a mouse model for the first time to provide a broader theoretical basis for the anti-inflammatory mechanism of propofol in AR and to provide laboratory evidence for its potential application in the treatment of AR in the future.

MATERIALS AND METHODS

Mouse Models

Sixty female 8-week-old BALB/c mice were purchased

from the animal experimental center of Guangdong province. The mice were fed in a pathogen-free room with humidity of 50%–70% and temperature of 22–24°C. Our experiment received approval from the Ethics Committee of Guangzhou Women and Children's Medical Center (Approval No. 261A01).

Establishment of Allergic Mice Model

Sensitization was achieved through the intraperitoneal injection of 100 µL of phosphate-buffer saline (PBS) (FengHao, China) or OVA (50 µg, Sigma Aldrich, USA) and 1.6 mg aluminum hydroxide [Al(OH)₃, Sigma Aldrich, USA] dissolved in PBS on days 0, 7, and 14 as previously described.¹⁴ Then, the challenge was performed by providing 20 µL of PBS or OVA (200 µg) intranasally on days 21, 22, and 23. Propofol (100 mg/kg, Sigma Aldrich, USA) was provided intraperitoneally half an hour before the challenge. The mice were grouped as follows (10 per group): (1) PBS (sensitization and challenge by PBS); (2) OVA (sensitization and challenge by OVA); (3) OVA + propofol (propofol treatment before challenge). The concentration of propofol was determined based on previous literature and our preliminary experiments.^{15,16}

Nasal Lavage Fluid Collection and Cell Counting

As described previously, cold PBS (1 mL) was inserted into the nasal cavity and collected in a tube.¹⁷ The collected samples were centrifuged and stored at –80°C for further analysis. Type II cytokines in the supernatant were tested using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, USA). The cell pellet was stained with Giemsa stain and counted to determine the number of eosinophils, lymphocytes, and total cells.

Determination of Nasal ILC2 Levels

The nasal tissues were obtained and minced for further use. After digestion with collagenase IV (1 mg/mL) (Fenghao, China) in Roswell Park Memorial Institute (RPMI) 1640 medium (Fenghao, China) for 2 hours, the cells were filtered through a strainer (70 µm and 40 µm) and collected for centrifugation. The percentage of the viable cells was determined using trypan blue staining (>96%). The mouse ILC2s were determined to be lineage negative CD3ε, CD11c, CD11b, Fc-epsilon receptor (FcεR)1α, γδ T cell receptor, B220, erythroid lineage (Ter-119), myeloid

Propofol Inhibited Type II Inflammation in Mice with Allergic Rhinitis

differentiation antigen (Gr-1), CD45⁺, CD127⁺, and suppression of tumorigenicity 2 (ST2)⁺ cells and were sorted via a FACS ARIA flow cytometer (BD Biosciences, USA) with purity >92%. IL-5⁺ ILC2 and IL-13⁺ ILC2 cells were confirmed using Cytotfix (BD Biosciences, USA).

Coculture of T_H2 and ILC2

CD4⁺ T cells were purified from the blood of the mouse models using magnetic beads. The percentage of viable cells was determined using trypan blue staining (>96%). The CD4⁺ lymphocytes (2×10⁵ cells per well) were incubated in a comprehensive culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin, all from Fenghao, China). T_H2 cells were prepared using an anti-murine CD3 antibody (concentration: 10 µg/mL) and an anti-murine CD28 antibody (concentration: 1 µg/ml), alongside murine IL-2 (10 ng/mL) and murine IL-4 (10 ng/ml) at 37°C, within a humidified environment containing 5% CO₂. All the antibodies were purchased from eBioscience (USA). The sorted ILC2s from mice were cultured with T_H2 cells (1:1) treated with propofol (30 µg/mL, eBioscience, USA), anti-major histocompatibility complex class II (anti-MHC II) monoclonal antibodies (mAb) (20 mg/mL, eBioscience, USA), propofol + anti-MHC II mAb for 96 hours as previously described. The T_H2 cell (CD3⁺CD4⁺IL-4⁺) proportion and type II cytokine levels in the supernatant were subsequently determined using flow cytometry and ELISA. The concentration of drugs was also determined based on previous literature and our preliminary experiments.^{9,18}

ELISA

The protein expression of cytokines was measured using ELISA kits (R&D systems, USA). The detection limits were as follows: IL-5, 3.9 pg/mL, IL-13, 125 pg/mL.

Quantitative Real-time Polymerase Chain Reaction

RNA was extracted from nasal tissue with TRIzol LS (USA). The RNA (1 µg) was reverse-transcribed to synthesize complementary DNA (cDNA). The relative expression of GATA binding protein 3 (*GATA3*) and RAR-related orphan receptor alpha (*RORA*) was detected via the ABI PRISM 7300 Detection System (USA). The relative expression of target genes was calculated via the $\Delta\Delta C_t$ method and corrected for the

beta-actin (*ACTB*) gene. The primers used in the test were as follows: *GATA3* sense, 5'-GCGGGCTCTATCACAAAATGA-3'; antisense, 5'-GCTCTCCTGGCTGCAGACAGC-3'; *RORA* sense, 5'-AAGGAGCCAGAAGGGATGAAC-3'; antisense, 5'-GGAACA ACAGACGCCAGTAAG-3'; *ACTB* sense, 5'-CGAAACTACCT TCAACTCCATC-3'; antisense, 5'-AGTGATCTCCTTCTGCAT CCT-3'.

Statistical Analysis

The data were analyzed using SPSS 18.0 with a *p* value of <0.05 indicating statistical significance. Comparison between groups was performed via the Mann-Whitney U test or Kruskal-Wallis H test.

RESULTS

Propofol Decreased Nasal Allergic Inflammation in Mouse Models

Allergic symptoms, OVA-specific IgE levels, and total numbers of cells, eosinophils, and lymphocytes in nasal lavage fluid (NLF) increased significantly after OVA sensitization and challenge (Figure 1). The propofol-treated mouse model presented with alleviated symptoms and decreased OVA-specific IgE levels, total number of cells, eosinophils, and lymphocytes in the NLF (Figure 1).

ILC2 Regulation by Propofol

In the OVA and propofol-treated group, the frequencies of nasal ILC2s, IL-5⁺ ILC2s, and IL-13⁺ ILC2s were lower than those in the OVA group (Figure 2). Moreover, the nasal expression of *GATA3* and *RORα* as well as the levels of IL-4, IL-5, and IL-13 were significantly inhibited after propofol treatment (Figure 2). The addition of anti-MHC II reversed the anti-inflammatory effect of propofol (Figure 2).

Propofol Inhibited Interaction Between ILC2s and T_H2 Cells Through MHC II

Compared with those cultured alone, cocultures of ILCs and CD4⁺ T cells resulted in significantly more T_H2 cells (Figure 3). When propofol was added, the percentage of T_H2 cells significantly decreased (Figure 3). However, this effect was alleviated when anti-MHC II was added (Figure 3).

Propofol Inhibited Type II Inflammation in Mice with Allergic Rhinitis




Figure 1. Establishment and intervention of an allergic rhinitis mouse model with propofol. **A and B.** Typical nasal symptoms after propofol treatments. **C.** Ovalbumin (OVA)-specific immunoglobulin E (IgE) levels were measured via enzyme-linked immunosorbent assay (ELISA). **D–F.** Total numbers of cells, eosinophils, and lymphocytes in the nasal lavage fluid of allergic mice after propofol treatment. * $p < 0.05$; PBS: phosphate-buffered saline; MHC II: major histocompatibility complex class II.

Propofol Inhibited Type II Inflammation in Mice with Allergic Rhinitis




Figure 2. Propofol inhibits group 2 innate lymphoid cell (ILC2) responses in a mouse model. A–C: The proportions of nasal ILC2s, interleukin (IL)-5⁺ ILC2s, and IL-13⁺ ILC2s after propofol treatment were determined via flow cytometry. **D and E:** Relative mRNA expression of GATA binding protein 3 (GATA3) and RAR-related orphan receptor alpha (ROR α) in nasal mucosa tissue. **F–H:** IL-4, IL-5, and IL-13 protein expression in nasal lavage fluid. * $p < 0.05$; PBS: phosphate-buffered saline; OVA: ovalbumin; MHC II: major histocompatibility complex class II; NLF: nasal lavage fluid.




Figure 3. Propofol inhibited the interaction between group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) cells through anti-major histocompatibility complex class II (anti-MHC II). Compared with those cultured alone, cocultures of ILC2s and CD4⁺ T cells resulted in significantly more Th2 cells. When propofol was added, the percentage of Th2 cells significantly decreased. However, this effect was alleviated when anti-MHC II was added. * $p < 0.05$.

DISCUSSION

In our study, we first demonstrated that propofol inhibited the proliferation and function of ILC2s as well as the interaction between ILC2s and Th2 cells, providing a new target for AR treatment.

AR is a common upper airway disease worldwide and is traditionally characterized by Th2 inflammation. ILC2s, a newly identified group of lymphoid cells, produce IL-5 and IL-13 after stimulation by epithelium-derived IL-25, IL-33, and thymic stromal lymphopoietin.¹⁹ An increasing number of studies have shown that ILC2s play a central role in the development of allergic inflammation.¹²

Propofol is a common intravenous anesthetic with bronchodilatory effects.^{20,21} Moreover, its anti-inflammatory effects have been confirmed in ischemia-reperfusion injury, lung injury, neuroinflammation, and various inflammatory cells, such as neutrophils, monocytes, macrophages, and T cells.⁸ Our results suggested that propofol inhibited OVA-induced allergic inflammation in a mouse model, as manifested by decreased infiltration of inflammatory cells and type II cytokines in NLF. Similarly, Jing et al suggested that propofol inhibited Th2-type inflammation in a mouse

model by promoting apoptosis during Th2 differentiation through activation of the GABA receptor.⁸ A study by He et al suggested that propofol anesthesia upregulated Th1 cytokine production and downregulated Th2 cytokines production in a rat model of spinal cord injury.²²

Our present study provided new evidence that propofol inhibits not only Th2 inflammation but also ILC2 inflammation. In propofol-treated mice, nasal ILC2 proliferation and type II cytokine production were significantly decreased. Our data revealed that the expression of ROR α and GATA3, key determinants of ILC2 differentiation and function, was also significantly inhibited by propofol.

A previous study confirmed that various cells, such as dendritic cells, B cells, and eosinophils can act as antigen-presenting cells by upregulation of MHC class II molecules.²³ Similarly, ILC2s also express MHC-II to act as antigen-presenting cells (APC).^{24,25} Previous studies have shown that MHC-II expressed by APCs is engaged in Th2 cell differentiation.²⁶ Consistently, our results also confirmed that propofol inhibited Th2 cell differentiation by downregulation of MHC class II expression.

Propofol Inhibited Type II Inflammation in Mice with Allergic Rhinitis

In conclusion, our study provides preliminary evidence for the first time that propofol inhibits the proliferation and function of ILC2s by decreasing the expression of transcription factors *GATA3* and *ROR α* as well as type II cytokines (IL-5 and IL-13). We also found that propofol suppressed the interaction between ILC2s and T_H2 cells mediated by MHC II. Our results suggest propofol can play an inhibitory role in AR by regulating both innate and adaptive immunity.

STATEMENT OF ETHICS

Our experiment received approval from the Ethics Committee of Guangzhou Women and Children's Medical Center (Approval No. 261A01).

FUNDING

This study was supported by grants from the Guangdong Special Support Plan for Top Young Talents.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

Not applicable.

Data Availability

The data supporting our findings are available upon reasonable request from the corresponding authors via email.

AI Assistance Disclosure

Not applicable.

REFERENCES

1. Zhang Y, Lan F, Zhang L. Update on pathomechanisms and treatments in allergic rhinitis. *Allergy*. 2022;77(11):3309-19.
2. Chen Y, Liang M, Zhu Y and Zhou D. [The effect of propofol and sevoflurane on the perioperative immunity in patients under laparoscopic radical resection of colorectal cancer]. *Zhonghua Yi Xue Za Zhi*. 2015;95(42):3440-4.
3. Dewachter P, Kopac P, Laguna JJ, Mertes PM, Sabato V, Volcheck GW, et al. Anaesthetic management of patients with pre-existing allergic conditions: a narrative review. *Br J Anaesth*. 2019;123(1):e65-e81.
4. Regli A, Sommerfield A, von Ungern-Sternberg BS. Anesthetic considerations in children with asthma. *Paediatr Anaesth*. 2022;32(2):148-55.
5. Kochiyama T, Li X, Nakayama H, Kage M, Yamane Y, Takamori K, et al. Effect of Propofol on the Production of Inflammatory Cytokines by Human Polarized Macrophages. *Inflamm Mediators*. 2019;17:2019:1919538.
6. Sehra S, Yao W, Nguyen ET, Ahyi AN, Tuana FM, Ahlfeld SK, et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. *J Immunol*. 2011;186(8):4959-66.
7. Morita Y, Ismail DM, Elkon KB and Chu CQ. Dichotomous response to transforming growth factor β after T cell receptor activation by naive CD4⁺ T cells from DBA/1 mice: enhanced retinoic acid receptor-related orphan nuclear receptor γ t expression yet reduced FoxP3 expression. *Arthritis Rheum*. 2011;63(1):118-26.
8. Cornish GH, Sinclair LV and Cantrell DA. Differential regulation of T-cell growth by IL-2 and IL-15. *Blood*. 2006;108(2):600-8.
9. Meng J, Xin X, Liu Z, Li H, Huang B, Huang Y, et al. Propofol inhibits T-helper cell type-2 differentiation by inducing apoptosis via activating gamma-aminobutyric acid receptor. *J Surg Res*. 2016;206(2):442-50.
10. Yamaguchi M, Shibata O, Nishioka K, Makita T and Sumikawa K. Propofol attenuates ovalbumin-induced smooth muscle contraction of the sensitized rat trachea: inhibition of serotonergic and cholinergic signaling. *Anesth Analg*. 2006;103(3):594-600.
11. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. *Nature*. 2010;464(7293):1367-70.
12. Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. *Chest*. 2019;156(1):141-9.
13. Lao-Araya M, Steveling E, Scadding GW, Durham SR and Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. *J Allergy Clin Immunol*. 2014;134(5):1193-5.e4.
14. Zeng Y, Zeng Q, Wen Y, Li J, Xiao H, Yang C, et al. Apolipoprotein A-I inhibited group II innate lymphoid cell response mediated by microRNA-155 in allergic rhinitis. *J Allergy Clin Immunol Glob*. 2024; 17;3(2):100212.

Propofol Inhibited Type II Inflammation in Mice with Allergic Rhinitis

15. Zhang Q, Wang L, Chen B, Zhuo Q, Bao C, Lin L. Propofol inhibits NF- κ B activation to ameliorate airway inflammation in ovalbumin (OVA)-induced allergic asthma mice. *Int Immunopharmacol.* 2017;51:158-64.
16. Li HY, Meng JX, Liu Z, Liu XW, Huang YG, Zhao J. Propofol Attenuates Airway Inflammation in a Mast Cell-Dependent Mouse Model of Allergic Asthma by Inhibiting the Toll-like Receptor 4/Reactive Oxygen Species/Nuclear Factor κ B Signaling Pathway. *Inflammation.* 2018;41(3):914-23.
17. Park JY, Choi JH, Lee SN, Cho HJ, Ahn JS, Kim YB, et al. Protein arginine methyltransferase 1 contributes to the development of allergic rhinitis by promoting the production of epithelial-derived cytokines. *J Allergy Clin Immunol.* 2021;147(5):1720-1731.
18. Jiang M, Liu H, Li Z, Wang J, Zhang F, Cao K, et al. ILC2s Induce Adaptive Th₂-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Mediators Inflamm.* 2019;20:2019:3140183.
19. Barnes PJ and Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med.* 1997;336(15):1066-71.
20. Chan AL, Juarez MM, Gidwani N and Albertson TE. Management of critical asthma syndrome during pregnancy. *Clin Rev Allergy Immunol.* 2015;48(1):45-53.
21. Grim KJ, Abcejo AJ, Barnes A, Sathish V, Smelter DF, Ford GC, et al. Caveolae and propofol effects on airway smooth muscle. *Br J Anaesth.* 2012;109(3):444-53.
22. He FY, Feng WZ, Zhong J, Xu W, Shao HY and Zhang YR. Effects of propofol and dexmedetomidine anesthesia on Th1/Th2 of rat spinal cord injury. *Eur Rev Med Pharmacol Sci.* 2017;21(6):1355-1361.
23. Hammad H, Plantinga M, Deswarte K, Pouliot P, Willart MA, Kool M, et al. Inflammatory dendritic cells--not basophils--are necessary and sufficient for induction of Th₂ immunity to inhaled house dust mite allergen. *J Exp Med.* 2010;207(10):2097-111.
24. Ohnmacht C, Schwartz C, Panzer M, Schiedewitz I, Naumann R and Voehringer D. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. *Immunity.* 2010;33(3):364-74.
25. Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. *Immunity.* 2014;41(2):283-95.
26. Phythian-Adams AT, Cook PC, Lundie RJ, Jones LH, Smith KA, Barr TA, et al. CD11c depletion severely disrupts Th₂ induction and development in vivo. *J Exp Med.* 2010;207(10):2089-96.